Patch Issues
The United States is currently facing a shortage of estrogen patches, which is leaving menopausal women struggling to access necessary hormone therapy. Experts are predicting that this situation may take a while to improve.
Interestingly, a recent study published in the New England Journal of Medicine suggests that a certain group of men could also find the treatment beneficial.
Researchers examined the effectiveness of transdermal estradiol, commonly known as estrogen patches, in treating patients with prostate cancer. This type of cancer involves the uncontrolled growth of cells in the walnut-shaped gland located below the bladder.
Statistics estimate that 1 in 6 men will be diagnosed with prostate cancer, and about 3% will succumb to it, making it the most prevalent cancer among men in the U.S., following skin cancer. It’s, notably, the second leading cause of cancer deaths in males after lung cancer.
In this recent study, prostate cancer patients received one of two treatments: tE2 estrogen patches or luteinizing hormone–releasing hormone antagonists, the latter being medications that reduce testosterone levels produced by the testicles.
Results indicated that those using estrogen patches fared slightly better. Their three-year survival rate without metastasis was 87.1%, in contrast to 85.9% for patients using hormone antagonists. Over five years, 81.1% of estrogen users were metastasis-free, compared to 79.2% for those receiving LHRH agonists.
However, what stood out were the side effects. A significant 89% of LHRH agonist patients reported experiencing hot flashes, while only 44% of estrogen patch users did. On the flip side, 85% of the estrogen patch group experienced breast enlargement, whereas just 42% of those on LHRH agonists reported the same.
Besides potentially aiding in cancer treatment, estradiol also appears to support brain health by enhancing neuroplasticity, decreasing inflammation, and improving communication among brain cells.
The promising results from estrogen patches add to ongoing advancements in the battle against prostate cancer. A recent Swedish study discovered that pioglitazone, a common diabetes medication, shows significant promise in controlling prostate cancer by not only slowing cell growth but also preventing recurrence.
Moreover, a study from UCLA demonstrated that an AI tool was able to identify prostate cancer with 84% accuracy versus 67% for doctors, showcasing AI’s potential to enhance diagnostic clarity.
While the overall five-year survival rate for prostate cancer can reach up to 97%, studies reveal that men who miss out on prostate cancer screenings are 45% more likely to die from the disease.
For those wanting to lower their prostate cancer risk, experts recommend a proactive approach: a long-term health study suggests that men who ejaculate 21 times or more each month have a 19 to 22% reduced risk of developing prostate cancer compared to those who do not.
